The most common adverse events with tirzepatide are gastrointestinal and dose-dependent. Most are transient and resolve as the body adjusts to the medication.
Common (>10%): nausea (25-31%), diarrhea (19-23%), decreased appetite (9-11%), vomiting (8-12%). Less common (1-10%): constipation, dyspepsia, abdominal pain, injection site reactions, fatigue, hypoglycemia (T2D patients on insulin/sulfonylureas). Serious (<1%): pancreatitis, gallbladder disease, kidney injury (typically dehydration-related), severe allergic reactions, severe hypoglycemia.
This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000